Search research articles
Contact Us
Filters
Showing results (31-40 of 71) with videos related to
Page
of 8
Sort By:
British Journal of Haematology
|
May 11, 2012
Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM
Shanti Natarajan-Amé, Sophie Park, Lionel Ades, et al.
Haematologica
|
October 17, 2024
Exposure toxicity of venetoclax in acute myeloid leukemia patients in the real-life setting: impact of high exposure on delayed neutropenia
Florent Puisset, Emmanuel Raffoux, Lionel Ades, et al.
Haematologica
|
November 21, 2024
FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome/ chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies
Pierre Peterlin, Joëlle Gaschet, Pascal Turlure, et al.
Haematologica
|
November 25, 2017
Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia
Etienne Lengline, Bernard Drenou, Pierre Peterlin, et al.
Oncotarget
|
May 18, 2017
BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia
Valérie Vidal, Guillaume Robert, Laure Goursaud, et al.
Blood Cancer Journal
|
July 19, 2024
Myeloid neoplasms arising after methotrexate therapy for autoimmune rheumatological diseases do not exhibit poor-risk molecular features
Mihir D Wechalekar, Lin-Pierre Zhao, Monika M Kutyna, et al.
Haematologica
|
May 10, 2007
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC)
Stéphane Vigouroux, Mauricette Michallet, Raphaël Porcher, et al.
Blood
|
August 11, 2011
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial
Thorsten Braun, Raphael Itzykson, Aline Renneville, et al.
Nature Communications
|
February 3, 2023
Myelodysplastic Syndrome associated TET2 mutations affect NK cell function and genome methylation
Maxime Boy, Valeria Bisio, Lin-Pierre Zhao, et al.
Leukemia Research
|
January 27, 2009
When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group)
Bruno Cassinat, Stéphane de Botton, Charikleia Kelaidi, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 71) with videos related to
Sort By:
Page
of 8
British Journal of Haematology
|
May 11, 2012
Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM
Shanti Natarajan-Amé, Sophie Park, Lionel Ades, et al.
Haematologica
|
October 17, 2024
Exposure toxicity of venetoclax in acute myeloid leukemia patients in the real-life setting: impact of high exposure on delayed neutropenia
Florent Puisset, Emmanuel Raffoux, Lionel Ades, et al.
Haematologica
|
November 21, 2024
FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome/ chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies
Pierre Peterlin, Joëlle Gaschet, Pascal Turlure, et al.
Haematologica
|
November 25, 2017
Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia
Etienne Lengline, Bernard Drenou, Pierre Peterlin, et al.
Oncotarget
|
May 18, 2017
BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia
Valérie Vidal, Guillaume Robert, Laure Goursaud, et al.
Blood Cancer Journal
|
July 19, 2024
Myeloid neoplasms arising after methotrexate therapy for autoimmune rheumatological diseases do not exhibit poor-risk molecular features
Mihir D Wechalekar, Lin-Pierre Zhao, Monika M Kutyna, et al.
Haematologica
|
May 10, 2007
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC)
Stéphane Vigouroux, Mauricette Michallet, Raphaël Porcher, et al.
Blood
|
August 11, 2011
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial
Thorsten Braun, Raphael Itzykson, Aline Renneville, et al.
Nature Communications
|
February 3, 2023
Myelodysplastic Syndrome associated TET2 mutations affect NK cell function and genome methylation
Maxime Boy, Valeria Bisio, Lin-Pierre Zhao, et al.
Leukemia Research
|
January 27, 2009
When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group)
Bruno Cassinat, Stéphane de Botton, Charikleia Kelaidi, et al.
Page
of 8